However, due to their robust nephroprotective effects, SGLT2 inhibitors are considered the preferred agents in patients with coexisting CKD, whereas GLP-1 RA may be particularly beneficial in individuals with concomitant obesity [70]. This evidence concerns the gene GLP1R and Obesity.